MedTech News
.................... by Andrew Celentano
Hematogenix’s MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb’s ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
Hematogenix’s proprietary Multiple Myeloma MRD (MM MRD) assay measured the primary efficacy endpoint cited in the FDA-approval of ZENBEXUS (iberdomide), reinforcing Hematogenix’s role as a specialized global leader in registrational oncology trials.
Turning brain neurons on and off with light: A reversible synaptic switch
A research team led by Professor Ji Won Um of the Center for Synapse Diversity and Specificity, Department of Brain Sciences, DGIST, in collaboration with a team led by Professor Alice Ting at Stanford University, has developed LATeNT, a novel optical control platform that uses light to block signal transmission between neurons and subsequently restore normal signaling. The work is published in the journal Nature Methods.
Single gene injection reverses inherited heart disease in mice and patient-grown tissue
Melbourne researchers have made a gene therapy breakthrough that could restore heart function in children with genetic heart disease, sparing them the need for transplants.
New norovirus vaccine approach may shape strategies for treating other RNA viruses as well
Every RNA virus—from stomach bugs and influenza to measles and the common cold—has its own story to tell, with a unique combination of symptoms, transmission rates, duration and chemical blueprint.
Ambient light activates wearable patch for wound treatment
A research team has developed a wearable patch that simultaneously promotes wound closure and tissue regeneration using room light or sunlight, without batteries or an external electrical power source. The work has been published online in Advanced Materials.
Heartbeats power a battery-free pacemaker designed to last a lifetime
Madison researchers have developed an implantable, battery-free pacemaker that’s charged by a patient’s heartbeat. The device has the potential to last an entire lifetime, reducing the risks and costs associated with replacing devices when their batteries fail.
‘Breakthrough’ mRNA cancer drug curbs melanoma in large trial
US drugmakers Merck and Moderna said Wednesday a personalized cancer treatment had shown success in reducing the recurrence of melanoma tumors in a late-stage trial hailed by experts as a “breakthrough.”
Human multi-organ chip tracks breast cancer spread to bone and lung
Cancer spreading beyond the primary tumor—a process known as metastasis—is responsible for at least two-thirds of cancer deaths. Drugs targeting metastatic progression have largely failed, in part because of the lack of predictive models that would help identify the underlying mechanisms of metastasis.